Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate By: News Direct June 28, 2023 at 15:49 PM EDT --News Direct--TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide.Contact DetailsProactive USA+1 347-449-0879na-editorial@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/transcode-therapeutics-making-preclinical-progress-with-lead-metastatic-cancer-candidate-175829166 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate By: News Direct June 28, 2023 at 15:49 PM EDT --News Direct--TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide.Contact DetailsProactive USA+1 347-449-0879na-editorial@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/transcode-therapeutics-making-preclinical-progress-with-lead-metastatic-cancer-candidate-175829166
--News Direct--TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide.Contact DetailsProactive USA+1 347-449-0879na-editorial@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/transcode-therapeutics-making-preclinical-progress-with-lead-metastatic-cancer-candidate-175829166